68888-19-7Relevant articles and documents
Novel quasi-scorpionate ligand structures based on a bis-N-heterocyclic carbene chelate core: Synthesis, complexation and catalysis
Yasar, Sedat,Cavell, Kingsley J.,Ward, Benjamin D.,Kariuki, Benson
, p. 374 - 382 (2011)
A series of novel quasi-scorpionate CNC donor ligands, MeC(2-C 5H4N){CH2(imidazole-R)} (R = methyl, n-butyl, n-propenyl), in which a chelating bis(NHC) core is supplemented by a hemi-labile pyridyl donor, were prepared. The coordination chemistry of these ligands was investigated with silver, palladium, rhodium and iridium. The single crystal X-ray structures of [Rh(NC2Me)(COD)]Cl 8a and [Ir(NC 2Pr)(COD)]Br 9b were determined. The catalytic potential of the rhodium and iridium complexes was assessed in the transfer hydrogenation of ketones; the iridium complexes, which show superior performance, form very effective and stable catalysts.
Iron-Catalyzed β-Alkylation of Alcohols
Bettoni, Leó,Gaillard, Sylvain,Renaud, Jean-Luc
supporting information, p. 8404 - 8408 (2019/10/16)
β-Branched alkylated alcohols have been prepared in good yields using a double-hydrogen autotransfer strategy in the presence of our diaminocyclopentadienone iron tricarbonyl complex Fe1. The alkylation of some 2-arylethanol derivatives was successfully addressed with benzylic alcohols and methanol as alkylating reagents under mild conditions. Deuterium labeling experiments suggested that both alcohols (2-arylethanol and either methanol or benzyl alcohol) served as hydrogen donors in this cascade process.
CERTAIN PLADIENOLIDE COMPOUNDS AND METHODS OF USE
-
, (2019/11/04)
The present disclosure provides novel pladienolide compounds, pharmaceutical compositions containing such compounds, and methods for using the compounds as therapeutic agents. These compounds may be useful in the treatment of cancers, particularly cancers in which agents that target the spliceosome and mutations therein are known to be useful. Also provided herein are methods of treating cancers by administering at least one compound disclosed herein and at least one additional therapy.
